Domperidone and sudden cardiac death: How much longer should we wait?

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 3, 2013, Pages 215-217

  Michaud, Veronique ^a,b   Turgeon, Jacques ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOMPERIDONE; KETOCONAZOLE; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; TERFENADINE;

CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HUMAN; IC 50; IN VITRO STUDY; LONG QT SYNDROME; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SUDDEN DEATH; SYSTEMIC CIRCULATION; TORSADE DES POINTES;

ANIMALS; ANTIEMETICS; DEATH, SUDDEN, CARDIAC; DOMPERIDONE; DOPAMINE ANTAGONISTS; FEMALE; HEART; HUMANS; MALE;

EID: 84875223232     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827e2573     Document Type: Note

References (37)

1. Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102:1883-1885.
2. Cisapride to be taken off market, placed in controlled-access plan. Am J Health Syst Pharm. 2000;57:834.
3. Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet. 1984;2:1336-1337.
4. Joss RA, Goldhirsch A, Brunner KW, et al. Sudden death in cancer patient on high-dose domperidone. Lancet. 1982;1:1019.
5. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed). 1984;289:1579.
6. Osborne RJ, Slevin ML, Hunter RW, et al. Cardiotoxicity of intravenous domperidone. Lancet. 1985;2:385.
7. Osborne RJ, Slevin ML, Hunter RW, et al. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol. 1985;4:617-626.
8. Bruera E, Villamayor R, Roca E, et al. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep. 1986; 70:545-546.
9. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998;97:204-210.
10. Hondeghem LM. Low safety index of domperidone: mechanism for increased odds ratio for sudden cardiac death. Acta Cardiol. 2011;66: 421-425.
11. Huizing G, Brouwers J, Westhuis P. Plasma drug concentration and prolactin release after acute and subchronic oral administration of domperidone and metoclopramide. In: Merkus F, ed. The Serum Concentration of Drugs. Amsterdam, Netherlands: Excerpta Medica; 1980:271-277.
12. Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6:61-70.
13. Wu MS, Gao L, Cai XH, et al. Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. Acta Pharmacol Sin. 2002;23:285-288.
14. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52:231-238.
15. Zhou Z, Vorperian VR, Gong Q, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol. 1999;10:836-843.
16. Chen X, Cass JD, Bradley JA, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol. 2005;146:792-799.
17. Whellan DJ, Green CL, Piccini JP, et al. QT as a safety biomarker in drug development. Clin Pharmacol Ther. 2009;86:101-104.
18. Layton D, Key C, Shakir SA. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf. 2003;12:31-40.
19. McCallum RW. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol. 1985;80:1008-1016.
20. Simard C, Michaud V, Gibbs B, et al. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34:1013-1023.
21. Ward BA, Morocho A, Kandil A, et al. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004;58:277-287.
22. Michaud V, Simard C, Turgeon J. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b(5) and inhibition by ketoconazole. Drug Metab Lett. 2010;4:95-103.
23. Interaction between ketoconazole and domperidone and the risk of QT prolongation - important safety information. S Afr Med J. 2006;96:596.
24. Michaud V, Turgeon J. Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probedrug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett. 2010;4: 69-76.
25. Morissette P, Hreiche R, Turgeon J. Drug-induced long QT syndrome and torsade de pointes. Can J Cardiol. 2005;21:857-864.
26. Duan JJ, Ma JH, Zhang PH, et al. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007;28:959-967.
27. Park SJ, Kim KS, Kim EJ. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J Appl Toxicol. 2008;28:104-111.
28. Kamiya K, Niwa R, Morishima M, et al. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci. 2008;108:301-307.
29. Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev. 2006;58:244-258.
30. Plante I, Vigneault P, Drolet B, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012;101:868-878.
31. Michaud V, Frappier M, Dumas MC, et al. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One. 2010;5:e15666.
32. Michaud V, Dumas M, Turgeon J. Domperidone and verapamil are metabolized by human heart microsomal fractions. Presented at: International congress of Clinical Pharmacology and Therapeutics, Quebec City, July 2008.
33. Lee CA, Neul D, Clouser-Roche A, et al. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos. 2010;38: 347-356.
34. Hennessy S, Leonard CE, Palumbo CM, et al. Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiol Drug Saf. 2008;17:1131-1136.
35. De Ponti F, Poluzzi E, Vaccheri A, et al. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol. 2002;54:171-177.
36. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med. 1999;107:356-362.
37. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.